In the heart of France’s Drôme region, a quiet town named Romans-sur-Isère has emerged as a critical global player in the nuclear fuel industry. What began 65 years ago as a small-scale operation has transformed into Europe’s largest nuclear fuel production hub, with its significance growing in both medical and scientific fields.
Amazon co-founder MacKenzie Scott has donated over $19 billion to charity in just five years
Diamond batteries powered by nuclear waste promise 28,000 years of clean energy
Romans-sur-Isère: A Historic Leader in Nuclear Fuel Production
For over six decades, Framatome has been manufacturing highly specialized nuclear fuels in Romans-sur-Isère. Originally established in 1959, the facility has long been at the forefront of nuclear technology, producing fuel elements for research reactors and targets for medical isotopes. Today, Framatome has officially expanded its operations with a new building that will enable them to meet the growing global demand for radio-isotopes and nuclear fuel.
The new addition to the site is a modern facility designed with state-of-the-art safety, security, and industrial performance in mind. The aim is simple: to ensure long-term, reliable production while continuing to lead in the radio-isotope sector, which has become essential for the medical industry worldwide.
A Legacy of Expertise and Innovation
The CERCA unit, part of Framatome, has been producing specialized fuels for non-electric reactors since its inception. Over the years, the plant has manufactured more than 20,000 fuel elements that have powered reactors around the world. Its focus is on reactors used for scientific research, material testing, and, most importantly, the production of medical isotopes.
Romans-sur-Isère holds a near-monopoly on this type of specialized production in Europe, making it a hub of global importance. The facility’s expertise is central to supporting the global nuclear transition, as Framatome helps advance small modular reactors (SMRs), reactivates experimental reactors, and ensures self-sufficiency in medical radio-isotopes.
The New “Uranium Zone” and Its Role in Modern Nuclear Fuel Production
At the core of the Romans-sur-Isère site is the “uranium zone,” a highly secure area where uranium powder is processed, compacted, and encapsulated into fuel elements. It’s here that targets for irradiating isotopes, like molybdenum-99, are created. Once placed in reactors, these targets generate technetium-99m, a key isotope used in millions of medical diagnoses globally.
Framatome’s latest investment replaces aging infrastructure with a completely revamped production line, incorporating the latest safety standards, radiological protection measures, and environmental considerations. The facility is now equipped to meet the growing demand for medical isotopes while maintaining the highest industry standards.
A Strategic Player in Global Medical and Research Networks
Romans-sur-Isère’s impact is immense but often goes unnoticed. Approximately 75% of all medical scans using technetium-99m come from targets produced in this French city. This isotope plays a crucial role in nuclear imaging, particularly in cardiology, oncology, and neurology, making it indispensable for millions of medical diagnoses each year.
NASA warns China could slow Earth’s rotation with one simple move
This dog endured 27 hours of labor and gave birth to a record-breaking number of puppies
Beyond its medical contributions, the CERCA unit also serves European research reactors, from Belgium to Hungary, and from France to the Netherlands. These reactors are essential for training nuclear engineers, developing new materials, and simulating extreme conditions for commercial reactors. The fuel produced in Romans must meet rigorous specifications, including high energy density, mechanical stability, and precise behavior under irradiation.
Romans-sur-Isère: A Global Nuclear Hub
Romans-sur-Isère is no longer just a quiet town in Drôme; it has become a strategic center for the global nuclear industry. The site’s inauguration, attended by international clients and local officials, signals its growing importance not only in scientific innovation but also in the international medical and nuclear landscape.
With its continued investment in modernizing the nuclear sector, Framatome’s facility in Romans-sur-Isère exemplifies the company’s vision of a sustainable, safe, and internationalized nuclear industry. It stands apart from the debates surrounding large-scale reactors, focusing instead on isotopes and the expertise that powers global medical advancements. As the world continues to demand clean energy and improved healthcare, Romans-sur-Isère will remain a critical piece of the puzzle in nuclear technology and medical innovation.